Arbutus Biopharma Corporation - Common Stock – Quartalsfinanzdaten (NASDAQ:ABUS)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -10.31 M-13.39 M-15.75 M-5.82 M-4.68 M-8.11 M -34.36 M Mittelzufluss aus Investitionstätigkeit 13.41 M11.35 M15.61 M-10.02 M-1.36 M2.2 M 6.43 M Zahlungsströme aus der Finanzierungstätigkeit 1.42 M2.78 M453 K844 K1.64 M11.62 M 14.56 M Freier Cashflow -10.31 M-13.39 M-15.75 M-5.82 M-4.68 M-8.11 M -34.36 M

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation - Common Stock

Nachrichten

Arbutus Biopharma: EPS übertrifft Schätzungen um 0,91 $ - Umsatz besser als erwartet

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna's Quarterly Earnings Preview: What You Need to Know

Arbutus Biopharma: EPS übertrifft Schätzungen um 0,02 $ - Umsatz besser als erwartet

Roivant Sciences-Aktie erreicht Allzeithoch von 30,31 USD/n

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Arbutus Biopharma: Chardan bestätigt Kaufempfehlung nach Vergleich mit Moderna/n

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang